## SAMANTHA D'ANNA

**PHD** 

Senior Healthcare Management Consultant

samantha.danna@milliman.com Main +1 860 687 0100 | Office +1 860 687 0186



# **Current Responsibility**

Samantha D'Anna is a senior healthcare management consultant with the Hartford office of Milliman. She joined the firm in 2015.

## **Professional Work Experience**

Samantha provides consulting services to insurance companies, pharmacy benefit managers, Medicare plan sponsors, government entities, and nonprofit organizations.

Her primary work includes assisting Medicare Part D plan sponsors and other groups with strategic decisions around prescription drug plan pricing within the context of the current regulatory environment.

### Education

- BA, Summa Cum Laude, Major: Psychology, Research Track, Minor: Neuroscience; University of Connecticut
- MA, Behavioral Neuroscience, University of Connecticut
- PhD, Behavioral Neuroscience, University of Connecticut

#### Presentations and Publications

- Co-author, <u>Possible outcomes of potential disclosure requirements in Medicare Part D</u>. Milliman White Paper, March 2023.
- Co-author, <u>Self-reported health status of Medicare Part D</u> <u>beneficiaries</u>. Millman Research Paper, November 2022.
- Co-author, <u>Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform</u>. Milliman Briefing Note, July 2022.
- Co-author, <u>A summary of insulin coverage in Medicare Part D</u>.
  Milliman Report, June 2022.
- Co-author, Medicare Part D pharmacy price concessions at the point of sale. Milliman Report, February 2022.
- Co-author, <u>A regulatory push to lower Part D costs at the pharmacy counter in 2023</u>. Milliman Report, January 2022.
- Co-author, <u>A demographic profile of Medicare Part D beneficiaries</u>. Milliman White Paper, November 2021.
- Co-author, <u>Reducing insulin costs for seniors: Thoughts for plan sponsors considering participation in the Medicare Part D Senior Savings Model</u>. Milliman White Paper, March 2020.

Co-author, <u>A new Part D benefit design? Prescription Drug Pricing</u>
 <u>Reduction Act proposes major changes to Part D</u>. Milliman White
 Paper, August 2019.

